| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Research Abstract |
Predictive markers for chemotherapeutic response are urgently needed to improve the outcomes of cancer treatment. We have previously found that intracellular S100A10 is expected to be one of the candidate predictive markers for response to oxaliplatin, a key drug for the treatment of colorectal cancer(CRC). In this study, we have demonstrated, by using CRC cells, that S100A10 is more specific to L-OHP than 5-fluorouracil and suggested the possibility that the interaction of S100A10 and annexin A2, the binding partner of S100A10, is potentially involved in the chemoresistance.
|
